MediWound Ltd. - Ordinary Shares (MDWD): Price and Financial Metrics

MediWound Ltd. - Ordinary Shares (MDWD): $13.30

0.04 (+0.30%)

POWR Rating

Component Grades













Add MDWD to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where MDWD ranks best; there it ranks ahead of 94.68% of US stocks.
  • The strongest trend for MDWD is in Stability, which has been heading down over the past 149 days.
  • MDWD's current lowest rank is in the Momentum metric (where it is better than 12.61% of US stocks).

MDWD Stock Summary

  • Equity multiplier, or assets relative to shareholders' equity, comes in at 10.27 for MEDIWOUND LTD; that's greater than it is for 90.8% of US stocks.
  • With a year-over-year growth in debt of 161.25%, MEDIWOUND LTD's debt growth rate surpasses 91.86% of about US stocks.
  • The volatility of MEDIWOUND LTD's share price is greater than that of 98.41% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MEDIWOUND LTD are HYMC, ESPR, CASA, LMDX, and PGEN.
  • MDWD's SEC filings can be seen here. And to visit MEDIWOUND LTD's official web site, go to

MDWD Valuation Summary

  • In comparison to the median Healthcare stock, MDWD's price/sales ratio is 73.68% higher, now standing at 3.3.
  • Over the past 110 months, MDWD's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MDWD.

Stock Date P/S P/B P/E EV/EBIT
MDWD 2023-03-24 3.3 8.0 -4.5 -6.9
MDWD 2023-03-23 3.1 7.6 -4.2 -6.3
MDWD 2023-03-22 3.2 7.8 -4.4 -6.6
MDWD 2023-03-21 3.1 7.5 -4.2 -6.2
MDWD 2023-03-20 3.0 7.2 -4.0 -5.8
MDWD 2023-03-17 3.0 7.2 -4.0 -5.8

MDWD Growth Metrics

    Its 2 year cash and equivalents growth rate is now at 108.63%.
  • Its 2 year price growth rate is now at -10.49%.
  • Its 5 year net cashflow from operations growth rate is now at 149.01%.
Over the past 15 months, MDWD's revenue has gone down $4,837,000.

The table below shows MDWD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 20.365 -16.12 -16.302
2022-06-30 20.934 -14.372 -15.448
2022-06-30 20.934 -14.372 -15.448
2022-03-31 22.323 -10.103 -14.289
2021-12-31 23.763 -8.916 -13.551
2021-09-30 24.949 -10.033 -11.123

MDWD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MDWD has a Quality Grade of D, ranking ahead of 14.08% of graded US stocks.
  • MDWD's asset turnover comes in at 0.824 -- ranking 31st of 681 Pharmaceutical Products stocks.
  • VRTX, CHUC, and AERI are the stocks whose asset turnover ratios are most correlated with MDWD.

The table below shows MDWD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.824 0.392 -1.189
2021-03-31 0.709 0.377 -0.788
2020-12-31 0.627 0.347 -0.555
2020-09-30 0.554 0.307 -0.464
2020-06-30 0.484 0.261 -0.326
2020-06-30 0.484 0.261 -0.326

MDWD Price Target

For more insight on analysts targets of MDWD, see our MDWD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.92 Average Broker Recommendation 1.33 (Strong Buy)

MDWD Stock Price Chart Interactive Chart >

Price chart for MDWD

MDWD Price/Volume Stats

Current price $13.30 52-week high $17.08
Prev. close $13.26 52-week low $8.05
Day low $13.01 Volume 24,443
Day high $13.44 Avg. volume 41,329
50-day MA $12.51 Dividend yield N/A
200-day MA $11.75 Market Cap 96.29M

MediWound Ltd. - Ordinary Shares (MDWD) Company Bio

MediWound Ltd. focuses on developing, manufacturing, and commercializing products for the treatment of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and others. The company was founded in 2000 and is based in Yavne, Israel.

MDWD Latest News Stream

Event/Time News Detail
Loading, please wait...

MDWD Latest Social Stream

Loading social stream, please wait...

View Full MDWD Social Stream

Latest MDWD News From Around the Web

Below are the latest news stories about MEDIWOUND LTD that investors may wish to consider to help them evaluate MDWD as an investment opportunity.

We Think MediWound (NASDAQ:MDWD) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | March 18, 2023

MediWound Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

MediWound ( NASDAQ:MDWD ) Full Year 2022 Results Key Financial Results Revenue: US$26.5m (up 12% from FY 2021). Net...

Yahoo | March 18, 2023

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -521.05% and 56.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 16, 2023

MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update

2022 total revenues of $26.5 million FDA approval of NexoBrid® in December 2022; U.S. commercial availability expected in the second quarter of 2023 EscharEx® Phase III protocol design is under review by the FDA; study to be initiated in the second half of 2023 Cash position of $66 million, including cash received for the NexoBrid approval milestone and recent equity financing Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd.

Yahoo | March 16, 2023

MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound’s Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the

Yahoo | March 16, 2023

Read More 'MDWD' Stories Here

MDWD Price Returns

1-mo 8.22%
3-mo -1.41%
6-mo 36.69%
1-year -4.52%
3-year 21.02%
5-year -63.46%
YTD -1.41%
2022 -18.34%
2021 -36.22%
2020 19.35%
2019 -23.65%
2018 -8.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.755 seconds.